Newtown, PA, September 27, 2010 – Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD® at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii. In vivo studies show that Ex-RAD®, upon oral administration, produced a significant increase in survival versus placebo-treated groups in mice exposed to lethal whole body irradiation (WBI), for both prophylactic pre-treatment and mitigation post-treatment. Ex-RAD® is the only known oral radioprotectant that has shown such activity in animal model systems.
Collectively, these presentations demonstrate the ability of Ex-RAD® to provide radioprotective benefit by injection and oral delivery, an in-depth understanding of the kinetics and metabolism of Ex-RAD®, and radioprotective benefit to human bone marrow, as well as the gastrointestinal and hematopoietic systems in mice.
Onconova, a biopharmaceutical company developing novel chemical entities to treat cancer and protect normal cells, is developing Ex-RAD®, a novel radioprotectant with potential utility in bio-defense or bio-terrorism, which could prove useful as a prophylactic agent for first-responder protection from the harmful effects of radiation from nuclear accidents or weapons of mass destruction (WMD).
These presentations result from an on-going Onconova collaboration among investigators at a number of institutions: AFRRI, (The Armed Forces Radiobiology Research Institute) a part of the Uniformed Services University of the Health Sciences (USUHS); Georgetown University, Department of Biochemistry and Molecular & Cellular Biology; Long Island University, Arnold & Marie Schwartz College of Pharmacy; and the Department of Oncological Sciences, Mt. Sinai School of Medicine.
Summary of Oral Ex-RAD® Findings
The results from a prophylactic radioprotection study in mice demonstrated that Ex-RAD® dosed orally or by injection prior to lethal whole body irradiation (WBI) produced significant enhancement in survival for both Ex-RAD® treated groups versus placebo.
Results from the radiomitigation experiment (where the drug is administered after exposure to lethal radiation), using both injection and oral methods of delivery demonstrated that Ex-RAD® treated animals had comparably high rates of survival in both groups.
Hence, oral Ex-RAD® was found to be effective in both prophylactic pre-treatment and mitigation post-treatment settings.
"Years of collaborative work are resulting in great progress with Ex-RAD® in the laboratory and the clinic and Ex-RAD® is the focus of several posters and a key presentation within the RSS scientific and educational track," said Manoj Maniar, PhD, Senior Vice President for Product Development of Onconova. "We are very excited to see the acceleration and new developments within radioprotection, specifically in oral prophylaxis and treatment. Ex-RAD® holds a unique position among developing products with the potential to benefit people exposed to whole body radiation."
Onconova oral presentation and poster sessions on Ex-RAD® at the Radiation Research Society meeting:
WEDNESDAY, SEPTEMBER 29, 2010
Poster Sessions – Radiation Protection – Protection / Mitigators / Treatment
SUNDAY, SEPTEMBER 26, 2:00 pm-2:45 pm, 2010, Haleakala Foyer
Poster Sessions – Experimental Therapeutics and Translational Research
WEDNESDAY, SEPTEMBER 29, 5:30 PM-6:15 PM, 2010 Haleakala Foyer
Ex-RAD® is a novel radiation protection drug developed in collaboration with the U.S. Department of Defense to protect against (when given pre-exposure) and provide treatment for (when given post-exposure) lethal radiation in models of tissue and whole body radiation injury. Unlike most radiation protectors, Ex-RAD® is not a free-radical scavenger, chelator or cell cycle arrestor – instead, Ex-RAD® accesses a novel mechanism for radiation protection involving intracellular signaling, damage sensing, and DNA repair pathways. Ex-RAD-treated cells sustain less DNA damage upon exposure to irradiation.
Two Phase I safety trials of Ex-RAD® have been completed in healthy human volunteers. The development of Ex-RAD® is advancing according to the FDA Animal Rule, under which approval is based upon establishing safety in human volunteers coupled with demonstration of efficacy in well-characterized animal models.
About Onconova Therapeutics, Inc.
Onconova, based in Newtown, PA and Princeton, NJ, discovers and develops novel small molecule therapeutics targeting signal transduction, cell-cycle regulation, and DNA repair. Onconova has a novel discovery platform focusing on non-ATP kinase inhibitors directed at validated and novel targets, and the company is also exploring a new immunoconjugate technology (comprising potent active compounds and proprietary linkers) for arming monoclonal antibodies for cancer therapy. These products, technologies and candidates are derived internally from a proprietary library of new chemical entities and non-ATP competitive chemotypes. In addition to Ex-RAD®, Onconova is also developing ESTYBON™ (ON 01910.Na, in Phase 3), an injectable and oral anti-cancer agent, as well as inhibitors of Plk2, ALK, CDK, JAK, and Bcr-Abl pathways. Currently, Onconova is conducting clinical trials at major centers in the USA and abroad for three product candidates. For additional information, please visit http://www.onconova.com.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.